

Bertrand Routy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2757068/publications.pdf>

Version: 2024-02-01

45
papers

9,952
citations

186265

28
h-index

254184

43
g-index

46
all docs

46
docs citations

46
times ranked

11235
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
2	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015, 350, 1079-1084.	12.6	2,539
3	<i>Enterococcus hirae</i> and <i>Barnesiella intestinihominis</i> Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016, 45, 931-943.	14.3	645
4	The gut microbiota influences anticancer immunosurveillance and general health. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 382-396.	27.6	389
5	Intestinal <i>Akkermansia muciniphila</i> predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	30.7	225
6	Cross-reactivity between tumor MHC class II-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	12.6	217
7	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
8	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020, 78, 195-206.	1.9	192
9	Moving towards personalized treatments of immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 504-515.	27.6	189
10	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1243-1250.	3.4	154
11	Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. <i>OncImmunology</i> , 2019, 8, e1568812.	4.6	148
12	The intimate relationship between gut microbiota and cancer immunotherapy. <i>Gut Microbes</i> , 2019, 10, 424-428.	9.8	98
13	Association Between Gut Microbiota and CD4 Recovery in HIV-1 Infected Patients. <i>Frontiers in Microbiology</i> , 2018, 9, 1451.	3.5	90
14	The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 343-354.	4.2	88
15	<i>Helicobacter pylori</i> infection has a detrimental impact on the efficacy of cancer immunotherapies. <i>Gut</i> , 2022, 71, 457-466.	12.1	87
16	A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota. <i>Cancer Discovery</i> , 2022, 12, 1070-1087.	9.4	86
17	The Bacterium <i>Akkermansia muciniphila</i> : A Sentinel for Gut Permeability and Its Relevance to HIV-Related Inflammation. <i>Frontiers in Immunology</i> , 2020, 11, 645.	4.8	84
18	Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. <i>Cancer Discovery</i> , 2021, 11, 2396-2412.	9.4	81

#	ARTICLE	IF	CITATIONS
19	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021, 28, 2778-2796.	11.2	72
20	The impact of the intestinal microbiota in therapeutic responses against cancer. <i>Comptes Rendus - Biologies</i> , 2018, 341, 284-289.	0.2	65
21	High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study. <i>European Journal of Cancer</i> , 2020, 139, 181-187.	2.8	65
22	The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. <i>Oncolmmunology</i> , 2017, 6, e1258506.	4.6	55
23	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	7.0	53
24	The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. <i>Oncolmmunology</i> , 2018, 7, e1434468.	4.6	51
25	Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. <i>European Journal of Cancer</i> , 2021, 142, 83-91.	2.8	48
26	Cancer Induces a Stress Ileopathy Depending on β^2 -Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. <i>Cancer Discovery</i> , 2022, 12, 1128-1151.	9.4	44
27	Metformin effect on gut microbiota: insights for HIV-related inflammation. <i>AIDS Research and Therapy</i> , 2020, 17, 10.	1.7	43
28	Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. <i>Thrombosis Research</i> , 2021, 205, 29-39.	1.7	35
29	Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. , 2022, 10, e004191.		23
30	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. <i>Oncolmmunology</i> , 2020, 9, 1774298.	4.6	22
31	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021, 27, 2571-2583.	7.0	22
32	Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers. <i>Oncolmmunology</i> , 2020, 9, 1836766.	4.6	15
33	Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1550-1559.	6.4	15
34	Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France. <i>Journal of Geriatric Oncology</i> , 2020, 11, 802-806.	1.0	14
35	Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. <i>Cell Death and Differentiation</i> , 2021, 28, 1532-1547.	11.2	11
36	First clinical proof-of-concept that FMT can overcome resistance to ICIs. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 325-326.	27.6	11

#	ARTICLE	IF	CITATIONS
37	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. , 2022, 10, e004241.		11
38	<i>Helicobacter pylori</i> serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2022, 11, .	4.6	11
39	FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 707-719.	4.6	10
40	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	6.9	9
41	Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2020, 9, 1794423.	4.6	7
42	COVID-19: a challenge for oncology services. <i>Oncolimmunology</i> , 2020, 9, 1760686.	4.6	7
43	Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation. <i>Current Oncology</i> , 2021, 28, 1045-1055.	2.2	7
44	The Link Between the Gut Microbiome and Response to Immune Checkpoint Inhibitors in Renal Cell Carcinoma. <i>European Urology</i> , 2021, 79, 1-2.	1.9	6
45	Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032). <i>BMJ Open</i> , 2022, 12, e053081.	1.9	3